Advertisement

Advances in Therapy

, Volume 36, Issue 10, pp 2927–2929 | Cite as

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

  • Marilyn K. GlassbergEmail author
  • Steven D. Nathan
  • Chin-Yu Lin
  • Elizabeth A. Morgenthien
  • John L. Stauffer
  • Willis Chou
  • Paul W. Noble
Open Access
Correction
  • 189 Downloads

Correction to: Adv Ther  https://doi.org/10.1007/s12325-019-01052-y

In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below
Fig. 2

Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Marilyn K. Glassberg
    • 1
    Email author
  • Steven D. Nathan
    • 2
  • Chin-Yu Lin
    • 3
  • Elizabeth A. Morgenthien
    • 3
  • John L. Stauffer
    • 3
  • Willis Chou
    • 4
  • Paul W. Noble
    • 5
  1. 1.University of Miami Health SystemMiamiUSA
  2. 2.Inova Fairfax HospitalFalls ChurchUSA
  3. 3.Genentech, Inc.South San FranciscoUSA
  4. 4.FibroGenSan FranciscoUSA
  5. 5.Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations